Julie joined GSK and was appointed as Chief Financial Officer Designate on 3 April 2023. She was appointed to the Board as Chief Financial Officer on 1 May 2023. She is a member of the GSK Leadership Team.
Prior to joining GSK, Julie was Chief Operating and Financial Officer and Executive Director, Burberry Group plc. Julie has an extensive life sciences background having been the Group CFO of Smith & Nephew from 2013 to 2017 and serving as a Non-Executive Director and Audit Chair of Roche Holding AG from 2016 to 2022. Before this, Julie was Interim Group CFO of AstraZeneca, having worked at the company for 25 years in finance, commercial and strategic roles in four countries and across three continents.
Julie is a Fellow of the Institute of Chartered Accountancy and the Institute of Tax. She qualified with KPMG International Limited.
Personal Details
Title: Ms
Surname: Brown
DoB: 01/01/1963
Age: 63 years
M/F: Female
Nationality: United Kingdom
Country of Birth: United Kingdom of Great Britain and Northern Ireland
Language: English
Qualification: Graduate Degree
Industry:
Qualifications & Experience
Industry Experience +5yrs:
Industry Qualification +5yrs?:
Finance experience +5yrs?:
Finance Qualification +5yrs:
Legal experience +5yrs?:
Delinquent director?:
Other Experiences?:
Collapsed company director?:
Other directorships (state)
(only entities turnover at least $5m p/a)
Working history
Committee/s
Company
Committee
Role
Appointment Date
Resignation Date
GlaxoSmithKline plc
Board
Member
01/05/2023
Independence Questions
Any family members working for the company?:
Are you doing business with the company?:
Do you hold shares in the company for more than 0.10%? (directly or by representation):
Is your Director annual fee more than 5% of your total income from all sources?:
Are you more than 10 years as a director?:
Are you an executive chairperson?:
InsidEntity has assumed that responses to the Independent Questions are NO as the company has not populated the information. The result will present the Director as Independent.